SCHEMBL7939890

SCHEMBL7939890

Nc1ncccc1NCc1cc(NC(=O)c2cc3cc(Cl)ccc3o2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
BACE1 P56817 4/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PTGDR2 Q9Y5Y4 3/20 0.42
HDAC1 Q13547 1/20 0.42
ADAMTS4 O75173 1/20 0.41
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
MMP13 P45452 1/20 0.41
MMP14 P50281 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
ATM Q13315 1/20 0.40
POLB P06746 1/20 0.40
BCAT1 P54687 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7941526 0.90 RAB9A (0.52) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL12301465 0.90 NPC1 (0.53) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL7945106 0.88 AURKA (0.47) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7940967 0.86 BACE1 (0.57) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7946768 0.86 NPC1 (0.47) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7939895 0.84 RXFP1 (0.51) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7943486 0.83 NPC1 (0.48) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7940477 0.83 MEN1 (0.46) NPC1RAB9AKMT2AMEN1BACE1
SCHEMBL7943303 0.82 BACE1 (0.52) BACE1
SCHEMBL7941927 0.82 POLB (0.46) NPC1RAB9ABACE1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 NPC1 431/4885RAB9A 1287/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.